Publications by authors named "Elisa Buffone"
Article Synopsis
- Early monitoring of adalimumab levels in patients with inflammatory bowel disease (IBD) may help predict clinical outcomes, specifically at week 2 of treatment.
- A study analyzed the relationship between week 2 serum adalimumab levels and clinical remission by identifying an optimal threshold level of 11.9 mcg/mL.
- Patients with levels above this threshold showed significantly higher odds of achieving clinical remission by week 12, suggesting that adjusting doses early could be beneficial for those below the threshold.
Background And Aims: It is unclear whether early symptom improvement in Crohn's disease [CD] provides any prognostic information for patients long-term. This paper aims to investigate the relationship between early patient-reported outcomes [PROs] after completion of induction of infliximab, and their relationship with long-term clinical remission [CR] and endoscopic remission [ER].
Methods: This post-hoc analysis [Clinicaltrials.